Given a document, an entity and its sentiment towards the entity, verify if it is the correct sentiment towards the entity. Answer should be yes or no. Note that URLs in the text have been replaced with [Link].

Q: Verify if the sentiment of the following document towards the entity Al Franken is Positive . (Reuters) -  U.S. Senator Al Franken   trying to salvage  his  political career  said on Sunday  he  does not plan to resign but called  himself  âembarrassed and ashamedâ by  his  behavior toward women who have accused  him  of groping or inappropriately touching them.
FILE PHOTO:  Senator Al Franken (D-MN)  meets with constituents at Minnesota Farmfest in Redwood County  Minnesota  U.S. August 6  2014. REUTERS/Craig Lassig/File Photo
 Franken   a Democrat and former comedian who has represented Minnesota in the Senate since 2009  said in a round of media interviews -- his first since the allegations surfaced on Nov. 16 -- that he looked forward to returning to his job on Monday.
âIâm embarrassed and ashamed. Iâve let a lot of people down and Iâm hoping I can make it up to them and gradually regain their trust â  Franken  told the Minneapolis Star Tribune.
 Franken  resisted comparisons between  his  behavior and that of Roy Moore  the Republican nominee for a U.S. Senate seat from Alabama who has been accused of improper conduct involving teenage girls decades ago.
âIâm going to take responsibility. Iâm going to be held accountable through the ethics committee â said  Franken   whose behavior is being investigated by the Senate ethics panel. âAnd Iâm going to hopefully be a voice in this that is helpful. ... Again  I respect women. What kills me about this is it gives people a reason to believe I donât respect women.â
When asked if he had considered resigning   Franken  said: âNo  no. The ethics committee is looking into this and I will cooperate fully with it.â
Pressed about stepping aside and allowing a woman to take his seat   Franken  told Minnesota Public Radio  âIâm committed to working as hard as I can here in the Senate for the people of Minnesota.â
 Franken  was first accused of sexual misconduct by radio broadcaster Leann Tweeden.  She  said  Franken  had forcibly kissed  her  during a 2006 USO war zone tour  and a photo showed him with his hands over  her  chest while  she  was sleeping.
Four days later  a woman named Lindsay Menz told CNN that  Franken  had touched  her  buttocks while the two were being photographed in 2010 at the Minnesota State Fair.
 Franken  has apologized to Tweeden  and has said  he  does not remember the incident with Menz. Last week  two other women told the Huffington Post Franken had touched their buttocks in separate incidents. The article did not provide the names of those two accusers.
âI donât remember these photographs  I donât â  Franken  told the Star Tribune. âThis is not something I would intentionally do.â
âI have been reflecting on this â  Franken  told Minnesota Public Radio of the allegations. âI want to be a better man.â
 Franken  is among a long list of celebrities and politicians who have been accused of sexual misconduct. The recent wave of accusations  some of them dating back for decades  began in October.

A: no
****
Q: Verify if the sentiment of the following document towards the entity Mohammad Shawash is Positive . Mohammad Shawashâs  partly restored storefront stands amid a sea of smashed concrete and debris-laden roads.
The 62-year-old with a snow-white beard and glasses decided to return to the historic souk five months ago to reopen the shop  he  had managed for years.
âI cried when I first came back. I found total destruction all around me. The stores were destroyed  the streets covered in rubble and rocks  and the buildings collapsed â  he  told AFP.
âSo I repaired it  myself   to prove to the whole world that Aleppoâs Old City still has a soul.â
â âI lost  myself â â
âI was raised here and I used to open my shop from 7:00am until late at night. I knew everyone around  me  â  he  said.
âItâs not just about losing money or stock. I lost my neighbours  I lost my people  I lost  myself .â

A: yes
****
Q: Verify if the sentiment of the following document towards the entity David Mitchell is Negative . David Mitchell  66  has multiple myeloma  a blood cancer that is incurable but treatable. To stay alive   he  takes $440 000 worth of drugs a year.  Mitchell  counts  himself  as lucky.  He  has Medicare and can afford to buy Medicare Supplement Plan B  so  his  insurance covers  his  drugs. But not everyone is so fortunate  which is why instead of quietly retiring in  his  60s   he  founded a nonprofit to take on high drug prices. Patients for Affordable Drugs launched earlier this year  and it’s already making noise. On August 29  for example  just one day before the Food and Drug Administration approved a groundbreaking new cancer therapy called Kymriah from the Swiss pharma company Novartis   Mitchell  was in a meeting with several Novartis executives to talk about its price.  Mitchell  did not know then that FDA approval was so imminent  but  he  did know that whenever Kymriah did get to market  it would be astronomically expensive. Kymriah is the first in the new class of therapies known as CAR-T  in which a patients’ own T cells are genetically engineered to go after cancer.  Mitchell  implored Novartis to price Kymriah fairly.
The next day  with FDA approval in hand  Novartis announced the new therapy would cost $475 000 per treatment. I spoke to  Mitchell  last week about  his  meeting with Novartis and  his  reaction to Kymriah’s pricetag. Ben Wakana  the executive director of Patients for Affordable Drugs  also joined parts of our conversation below. Their campaign  while relatively new  is an extremely polished one. Before working on Patients for Affordable Drugs  Mitchell was a partner at GMBB  a communications firm perhaps best known for cutting ads for Democrats  and Wakana was spokesperson for the Department of Health and Human Services. The nonprofit is funded with half a million from the Laura and John Arnold Foundation in addition to $75 000 of Mitchell’s own savings and another $75 000 they have since fundraised. A transcript of our conversation  edited and condensed for clarity  is below. Butch Ramsey Sarah Zhang: So how is your health these days? David Mitchell: My health status is great. I’m a very lucky man. The drugs I’m using are working and I am tolerating them very well. I am relapsed  so I'm into the second line of drugs. Myeloma finds its way around drugs. It mutates and changes  so I need new drugs and innovation if I want to live as long as I hope to. You know  watch my youngest son graduate from college  that'd be cool. Have a grandchild  that would be cool.
Ben Wakana: You would have to ask Novartis. I will throw out a hypothesis  which is we sent Novartis a letter and said we’re asking you to price this drug fairly. At the same time we started a petition where we said to people  “Tell Novartis to price this drug in accordance with the fact that U.S. taxpayers spent $200 million researching CAR therapy.” In within 11 days  we got 3 455 people to sign that petition. I would like to think when patients speak up  and we're an organization that represents patients  that has an impact on people. Now it could just have been [then Novartis CEO] Joseph Jimenez was in a good mood one day and told his folks to meet with us. Zhang: How did the meeting with Novartis go? Mitchell: [laughs] It was a very polite meeting—what do they call it in diplomatic circles? There was a frank exchange. It was about an hour and 15 minutes long. Novartis talked maybe 45 or 50 minutes of that hour and 15  and mainly they explained to us why the drug had to be so expensive and why “financial toxicity” is not their fault; it's the fault of the health-care system   it 's insurers   it 's pharmacy benefit managers   it 's doctors  hospitals  it's everything else  it's not them. They're innovators  and the problem is a screwed-up system. And then they spent a lot of time explaining why the drug had to be so expensive. We hoped to actually have a discussion. They just told us why it had to be expensive. They used a word that drug companies often use in conversations that I have had with them. They said  “It’s very complex  David.”
Zhang: As you know  Novartis disputes the $200 million figure because not all of that money went directly to CAR-T for cancer or toward the specific therapy behind Kymriah.  Mitchell : We're going to send you a clip from a blog post by Francis Collins  the head of the National Institutes of Health  in which  he  explains the long history of NIH in building the foundational science for CAR-T. Here's our position: From 1993 until 2017  NIH invested more than $200 million in the overall science of CAR-T. Even the seminal paper that was published in August of 2011 by Dr. Carl June of the University of Pennsylvania was funded in part by the NIH. All of the makers—Novartis  Kite (which will become Gilead)  and Juno [other companies pursuing CAR-T cell therapy]—are standing on that foundational science. The taxpayers invested early when the risk was the greatest. Zhang: What do you think is a fair price for Kymriah? Mitchell: Well  we have run the numbers a variety of different ways. Now  the point is no one knows the real numbers except Novartis  so we go back to the statements in a Reuters article in 2015 where Kite’s chief financial officer said they thought the base price was $150 000 for treatment  and analysts at that time were saying [costs could be] up to $300 000. When we tried to model  we can’t get over $300 000. Zhang: Novartis did take two unusual steps when announcing the price of Kymriah. First  they pointed to a British analysis to say they actually thought Kymriah was worth $600 000 to $750 000 but they were going to price it lower at $475 000. And second  they said patients who don’t respond after 30 days to the treatment will not have to pay.
Mitchell: Now we don't know if that's the right end point because it turns out over 20 percent of people relapse in six months. So maybe it would more genuine of them to suggest they give a refund to people who relapse at six months or within six months. “It's not about you as one individual company; it's about the emergence of a new class of therapy.” Zhang: Why did you set your sights on Novartis and their therapy Kymriah in the first place? Mitchell: First of all  we work on all drugs. We work with people who have all diseases from high blood pressure and cardiac disease to multiple sclerosis and cystic fibrosis. However  we decided that it was important to focus on the emergence of a whole new class of therapies. We need to put focus and energy on CAR-T and Novartis got our attention because it's first. And we told them that when we went to visit with them. It's not about you as one individual company; it's about the emergence of a new class of therapy. Zhang: What else does Patients for Affordable Drugs do?  Mitchell : This week we're incredibly busy. We're helping support a rally at Eli Lilly to protest the skyrocketing prices of insulin. Insulin prices have increased more than 300 percent in the last decade. It's outrageous and people are suffering because of it. There's a rally at Eli Lilly September 9  and we'll be supporting that. One of our staff is getting on a plane to go to California to help work in support of SB-17  which is a bill in California for transparency and early notification of drug price increases. We are mobilizing our community out there and will in fact have one of our patients at a news conference there.

A:
no
****